13 October 2022 – PLC would like to congratulate Neurelis’ recent presentation of data from their long-term safety study of VALTOCO® in the pediatric population. PLC has provided clinical oversight of the safety study and continues to support Regulatory filings for VALTOCO on behalf of Neurelis in the US.
NEURELIS PRESENTS NOVEL, INVESTIGATIONAL ANALYSIS OF VALTOCO® (DIAZEPAM NASAL SPRAY) CIV DEMONSTRATING INCREASED TIME BETWEEN SEIZURE CLUSTERS AT THE 51ST CHILD NEUROLOGY SOCIETY ANNUAL MEETING
- Two posters highlight findings from a long term safety study of VALTOCO in a pediatric population
- The first features investigational data indicating a doubling of time between VALTOCO treated seizure clusters across 12 months
- The second summarizes a sub-analysis showing no long-term safety differences for VALTOCO in patients with Lennox-Gastaut Syndrome and other pediatric epileptic encephalopathies